Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Estey

Showing results (161-170 of 204) with videos related to

Pageof 21
Sort By:
Cancer|May 15, 2009
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemiaGautam Borthakur, E Lin, Nitin Jain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1989
Response to salvage therapy and survival after relapse in acute myelogenous leukemiaM J Keating, H Kantarjian, T L Smith, et al.
Cytokines and Molecular Therapy|June 1, 1995
Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantationS Giralt, S O'Brien, M Talpaz, et al.
Cancer|April 28, 2011
Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemiaFabio P S Santos, Dan Jones, Wei Qiao, et al.
Leukemia|October 1, 1996
Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adultsS M Kornblau, V Gandhi, H M Andreeff, et al.
The Journal of Clinical Investigation|September 19, 2001
Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemiaM Milella, S M Kornblau, Z Estrov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome?C K Murray, E Estey, E Paietta, et al.
Leukemia|August 2, 2001
Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromeS Verstovsek, H Kantarjian, E Estey, et al.
Leukemia|June 14, 2013
Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD AndersonM Othus, H Kantarjian, S Petersdorf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 1999
The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogeneticsS M Kornblau, P F Thall, Z Estrov, et al.
Pageof 21

Showing results (161-170 of 204) with videos related to

Sort By:
Pageof 21
Cancer|May 15, 2009
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemiaGautam Borthakur, E Lin, Nitin Jain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1989
Response to salvage therapy and survival after relapse in acute myelogenous leukemiaM J Keating, H Kantarjian, T L Smith, et al.
Cytokines and Molecular Therapy|June 1, 1995
Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantationS Giralt, S O'Brien, M Talpaz, et al.
Cancer|April 28, 2011
Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemiaFabio P S Santos, Dan Jones, Wei Qiao, et al.
Leukemia|October 1, 1996
Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adultsS M Kornblau, V Gandhi, H M Andreeff, et al.
The Journal of Clinical Investigation|September 19, 2001
Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemiaM Milella, S M Kornblau, Z Estrov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome?C K Murray, E Estey, E Paietta, et al.
Leukemia|August 2, 2001
Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromeS Verstovsek, H Kantarjian, E Estey, et al.
Leukemia|June 14, 2013
Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD AndersonM Othus, H Kantarjian, S Petersdorf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 1999
The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogeneticsS M Kornblau, P F Thall, Z Estrov, et al.
Pageof 21